Replies to post #219776 on Biotech Values

[DewDiligence]

SPHS +22% on claimed blamelessness for patient death:

https://www.prnewswire.com/news-releases/sophiris-bio-updates-on-phase-2b-localized-prostate-cancer-trial-300703992.html

Still, the stock remains about 20% below the pre-selloff price on 6/22/18.